Clinical Efficacy Evaluation of Sirolimus in Congenital Hyperinsulinism
Background. Congenital hyperinsulinism (CHI) is a rare and life-threatening genetic disorder. Sirolimus as a mammalian target of rapamycin inhibitor may be helpful in patients with CHI who do not respond well to other treatments including diazoxide and octreotide. However, the safety and efficacy of...
| Published in: | International Journal of Endocrinology |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Online Access: | http://dx.doi.org/10.1155/2020/7250406 |